Abstract
Purine nucleoside phosphorylase (PNP) deficiency is an immunodeficiency disorder characterized by recurrent infections, failure to thrive and neurologic symptomatology. While enzyme replacement therapy (ERT) is a therapeutic option for adenine deaminase (ADA) deficiency, a similar disorder, this is not available for PNP deficiency, and bone marrow transplant (BMT) is the only treatment option. Moreover, even with BMT, improvement of neurological deficits is not definite. We describe a 16-month-old boy who underwent BMT for PNP deficiency which resulted not only in freedom from infections but also in neurological improvement and autologous T-cell recovery.
Pre-transplant, this child had severe lymphopenia with recurrent infections and psychomotor retardation. Post-transplant, in the presence of mixed chimerism, he had normal lymphocyte count, including presence of recipient T cells and neurological improvement. The re-emergence of recipient T cells, when there were virtually no such cells pre-transplant, and the neurological improvement are indicative of improvement of the enzyme deficiency in tissues which remain genetically enzyme depleted.
These defects are not directly corrected by BMT, but are due to delivery of the missing enzyme by the transplanted tissue. In this aspect, transplantation in PNP deficiency is similar to transplantation in other inborn errors of metabolism where the engrafted donor cells deliver enzyme and restore function to deficient tissues. This further lends support to the recommendations that BMT should be the favoured treatment option in disorders like ADA deficiency or Hurler syndrome, where, even though ERT is available, it is limited by inability to correct the central nervous system defects.
Competing interests: None declared
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Asheuer M, Pflumio F, Benhamida S et al (2004) Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci USA 101:3557–3562
Booth C, Gaspar HB (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3(1):349–358
de Ru MH, Boelens JJ, Das AM et al (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with Mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6(1):55
Desnick RJ, Schuchman EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954–966
Hallett RJ, Gaspar B, Duley JA et al (1999) Allogeneic bone marrow transplantation corrects the immunodeficiency in PNP deficiency but does not reverse the neurological abnormalities. Cell Mol Biol Lett 4:374
Hershfield MS (1995) PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 5:107
Hershfield MS, Mitchell BS (2001) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 2585–2625
Hirshhorn R, Canotti F (2007) Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith CIE, Puck JM (eds) Primary immunodeficiency diseases: a molecular and genetic approach, 2nd edn. Oxford University Press, New York, pp 169–196
Hoogerbrugge PM, Brouwer OF, Bordigoni P et al (1995) Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 345:1398–1402
Myers LA, Hershfield MS, Neale WT et al (2004) Purine nucleoside phosphorylase deficiency presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation. J Pediatr 145(5):710–712
Priller J, Flügel A, Wehner T et al (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7:1356–1361
Wynn RF, Wraith JE, Mercer J et al (2009a) Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr 154:609–611
Wynn RF, Stubbs M, Ozyilmaz N et al (2009b) Cellular therapy of lysosomal storage disorders: current status and future prospects. Curr Pediatr Rev 5:147–159
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Verena Peters
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Singh, V. (2012). Cross Correction Following Haemopoietic Stem Cell Transplant for Purine Nucleoside Phosphorylase Deficiency: Engrafted Donor-Derived White Blood Cells Provide Enzyme to Residual Enzyme-Deficient Recipient Cells. In: JIMD Reports - Case and Research Reports, 2012/3. JIMD Reports, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2012_126
Download citation
DOI: https://doi.org/10.1007/8904_2012_126
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28128-0
Online ISBN: 978-3-642-28129-7
eBook Packages: MedicineMedicine (R0)